Studies conducted at Inflamax Research culminate with clinical trial deliverables to clients and study Sponsors as well as with the publication of R&D outcomes and innovations.
Our new State-Of-The-Art facility has the finest technology, optimum processes and procedures, and operates with highly knowledgeable and experienced staff to assure clinical trials are carried out to global ICH-GCP standards.
We offer the conduct of clinical trials for therapeutic areas that require tight environmental controls by use of EECs. Fully electronic systems have been developed to facilitate the drug and device R&D process of sponsoring organizations.
"Our mission at Inflamax is to use our scientific expertise and experience to provide the highest quality pharmaceutical research services worldwide."
Upcoming Meetings To schedule a time to meet with us at any of the upcoming events we will be attending, please click the Schedule link after the event listing.
|
“Next Generation”
|
Study Volunteers We are currently looking for healthy males and females for research studies! 
|
Released May 21, 2013
Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
Inflamax Research today announces a collaboration with the Immune Tolerance Network (ITN), which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), to conduct clinical research into the underlying mechanisms of allergy.
Inflamax scientists worked closely with internationally renowned expert scientists of the ITN to design the study, which will provide critical insight into the usefulness of two key clinical models used in the study of allergy treatments, the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC) models. Although both the models are well recognized and supported by numerous publications, to date no direct comparison between the allergic responses evoked by them has been performed... Read Full Story
Released April 9, 2013
Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Inflamax Research Inc. today announced that it has been selected by Allergy Therapeutics (UK) Ltd. (ATL) (AGY:LSE), as the CRO to conduct ATL’s pivotal Phase III study for Grass MATAMPL product for US-FDA registration.
The study will involve the location of mobile EEC at centers in three metropolitan areas in the US Midwest, US North East and in Canada, with several investigative sites at each node contributing subjects to the study. The screening and dosing will take place at the investigator site and the subject will be sent to the mobile EEC, located close to the investigator site, for EEC related activities.
Inflamax will operate the... Read Full Story
Date: February 27, 2013 2:14pm EST
Inflamax Research recently presented three posters at an Allergy and Immunology conference. The topics of the posters were the following:
All three posters are available for viewing in PDF format by clicking on the topic (above).
Released February 18, 2013
Inflamax Research Inc., a specialty Clinical Research Organization focused on allergy and asthma research utilizing their Next Generation Environmental Exposure Chamber (EEC) technology, today announced the appointment of Dr. Anne Marie Salapatek as President & CSO.
Dr. Salapatek is an internationally renowned scientist with expertise in allergy, asthma and EEC clinical trials. Previously she was the Principal Scientist at Cetero Research (formerly Allied Research International) where she was responsible for the development and validation of new Allergy and Asthma clinical models, advising clients on study designs including utilizing EEC technology for seasonal and perennial allergies, asthma, non-allergic rhinoconjunctivitis and COPD. Dr. Salapatek has worked with many... Read Full Story
Copyright © 2012 - All Rights Reserved - www.InflamaxResearch.com
 |
 |
 |
 |